On December 1, 2022 Cellectis (the "Company") (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, reported that it will host a live webcast to review the Company’s clinical data on the AMELI-01 study (evaluating UCART123) presented at the ASH (Free ASH Whitepaper) Annual Meeting, and provide a Company update, on December 13, 2022 (Press release, Cellectis, DEC 1, 2022, View Source [SID1234624662]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The event will feature presentations by the management team and will be followed by a Q&A.
Cellectis Live Webcast
Tuesday, December 13, 2022
7:30am ET/1:30pm CET
To register and access the live webcast: View Source
Following the live webcast, a replay will be available under the "Events and Webcasts" section on the Investor page of the Company’s website: View Source